We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| hVIVO Plc | AQSE:HVO.GB | Aquis Stock Exchange | Ordinary Share | GB00B9275X97 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.50 | -2.50% | 19.50 | 18.50 | 20.50 | 20.62 | 19.50 | 20.00 | 61,841 | 10:10:12 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jan 2020 to Jan 2025
TIDMHVO
RNS Number : 3407Z
hVIVO plc
09 January 2020
HVIVO plc
("hVIVO" or the "Company")
Exercise of Share Options
London, UK, 09 January 2020: hVIVO plc (AIM: HVO), an industry leading clinical development services business supporting product development for companies developing antivirals, vaccines and respiratory therapeutics, announces that, following the exercise of employee share options by an ex-employee, application has been made to AIM for the admission of 15,116 new ordinary shares of 5 pence each (the "New Ordinary Shares"). Admission to trading on AIM of the New Ordinary Shares ("Admission"), which will rank pari passu in all respects with the Company's existing shares in issue, is expected to occur on 15 January 2020.
Following Admission, the total number of ordinary shares with voting rights in issue will be 83,599,062 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
For further information please contact:
hVIVO plc Anesh Patel (Interim Finance Director & Company Secretary) +44 207 756 1300 Fleur Wood (EVP, Investor Relations & Communications) Numis Securities Limited +44 207 260 1000 Freddie Barnfield / Huw Jeremy (Nominated Adviser) James Black (Corporate Broking) FTI Consulting Simon Conway / Victoria Foster Mitchell +44 203 727 100
Notes to Editors:
hVIVO is an industry leading clinical development services business supporting product development for customers developing antivirals, vaccines and respiratory therapeutics. Leveraging human disease models in human rhinovirus (HRV), RSV, Influenza (Flu) Asthma and chronic obstructive pulmonary disease (COPD), the hVIVO platform illuminates the entire disease cycle in people from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted 56 clinical studies and inoculated over 2900 volunteers.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
IOEBXGDBLDGDGGC
(END) Dow Jones Newswires
January 09, 2020 08:29 ET (13:29 GMT)
1 Year hVIVO Chart |
1 Month hVIVO Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
